Immunotherapeutic methods and molecules
AssigneeCell Medica, Inc.
InventorMax Stanley Topp
Life of this patent
Estimating the term…
Abstract
A peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTI DWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two of the amino acid residues are altered, wherein the portion or variant is capable of binding HLA-DRB1*04. The peptide, certain polypeptide fusion molecules and certain polynucleotides encoding the same may be useful in combating Aspergillus infection or allergies. In particular, they may be used in processes for preparing Aspergillus-specific T cells for adoptive immunotherapy.
Claims84
A complex comprising a Class II HLA-DRB1*04 molecule bound to a peptide, wherein the peptide is a peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTIDWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA DRB1*04.
4-5. (canceled)
A method for selecting, isolating or identifying Aspergillus-specific T cells, the method comprising contacting a population of T cells with a peptide presented in a Class II HLA-DRB1*04 molecule, wherein the peptide is a peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTIDWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA DRB1*04.
10-11. (canceled)
Aspergillus-specific T cells which are able to recognise the HLA-DRB1*04-presented peptide FHTYTIDWTKDAVTW.
15-17. (canceled)
20-22. (canceled)
(canceled)
A peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTIDWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA DRB1*04.
A peptide consisting of the amino acid sequence FHTYTIDWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the portion or variant is capable of binding HLA DRB1*04.
(canceled)
(canceled)
40-43. (canceled)
(canceled)
(canceled)
50-51. (canceled)
(canceled)
(canceled)
59-61. (canceled)
63-64. (canceled)
An antibody which selectively recognises the peptide FHTYTIDWTKDAVTW when presented by Class II HLA-DRB1*04.
66-67. (canceled)
(canceled)
Dependencies are inferred from the claim text.